Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tigecycline - Pfizer

Drug Profile

Tigecycline - Pfizer

Alternative Names: GAR 936; TBG-Mino; Tigilcycline; Tygacil; WAY 156936; WAY-GAR-936

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antibacterials; Glycylcyclines; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Discontinued Diabetic foot ulcer; Mycobacterial infections; Nosocomial pneumonia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Apr 2018 Antimicrobial data from an in vitro study presented at the the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top